Despite palliative chemotherapy (cyclophosphamide and vincristine), the patient experienced rapid tumor recurrence and progressive clinical deterioration, culminating in death three weeks post-intervention. In resource-limited settings, where advanced molecular diagnostics are scarce, maintaining a high index of clinical suspicion and ensuring multidisciplinary management are paramount. Early histopathological confirmation is critical to addressing the rapid progression and therapeutic resistance characteristic of this malignancy.

Six prognostic genes, particularly RAB25 and PLAU, influence ESCC progression and immune microenvironment remodeling.

Interestingly, aCD7P-VCR treatment substantially reduced leukemia progression and invasion in the orthotopic CCRF-CEM T-ALL model without toxic effects, leading to significantly longer survival than clinically used VCR and nontargeted P-VCR. aCD7P-VCR is expected to provide an effective and targeted therapeutic approach for T-ALL.

She was managed according to the Chinese Children Cancer Group (CCCG)-WT-2019 protocol, receiving neoadjuvant VAD (vincristine, actinomycin D, and doxorubicin) chemotherapy, followed by staged bilateral nephron-sparing surgery. This highlights the limitations of current histology- and stage-based approaches for specific molecular subtypes. Current evidence supports more aggressive surgical intervention for high-risk cases, but it is essential to balance the need for renal function preservation with the goal of achieving oncological control.

The boy had surgery to remove the affected tonsil and lymph nodes, followed by chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Given the tumor's high growth rate and risk of spreading early, treatment needed a team approach that involved complete local removal and immediate systemic therapy. Long-term follow-up is important, and more case reports and studies are necessary to determine the best treatment options and improve results in pediatric histiocytic sarcoma.

Albendazole was administered in two doses separated by two weeks with clinical resolution; the patient remains under outpatient surveillance. This case highlights that ectopic enterobiasis can mimic cervical lymphadenopathy and metastatic disease, particularly in immunocompromised patients, and that histopathology is critical for diagnosis and management.

Among the pharmacogenetic factors influencing toxicity of commonly used B-ALL treatments, variants in the TPMT and NUDT15 genes, both involved in the metabolism of 6-mercaptopurine, represent the most robust and clinically validated predictors. Emerging evidence also links additional genetic variants to toxicities associated with other key agents used in ALL treatment regimens, including variants in SLCO1B1 associated with methotrexate-related gastrointestinal toxicity and variants in CEP72 associated with vincristine-induced neuropathy. The integration of pharmacogenomic biomarkers into clinical protocols, enabling genotype-guided dose adjustment, may represent a valuable strategy to avoid toxicity and improve overall cancer outcomes. However, further studies and innovative approaches are required to validate emerging biomarkers and facilitate their translation into routine clinical practice.

P3, N=395, Completed, Children's Oncology Group | Trial completion date: Nov 2026 --> Mar 2026 | Active, not recruiting --> Completed

P3, N=808, Completed, Children's Oncology Group | Active, not recruiting --> Completed

Upon initial admission, they were misdiagnosed with nephroblastoma and received radical nephrectomy and vincristine chemotherapy. Pathological consultation and advanced molecular sequencing identified specific expression of the BCL6 corepressor gene in patient tumor tissue, leading to a definitive diagnosis of CCSK. Furthermore, the present study aimed to provide an overview of the aberrant genes associated with CCSK to provide a useful reference for future research on the pathogenesis of CCSK and improvement of molecular pathology.

Three cycles of VAC (vincristine + actinomycin D + cyclophosphamide) combination chemotherapy and another cervical conization surgery were taken out for maximum therapeutic effect. This rare case reminds us that the tumor diagnosis should always be taken into consideration for any unexpected mass. A multi-disciplinary team including gynecologist, pediatrician, oncologist, radiologist, and pathologist could be a good choice to avoid such a pitfall of misdiagnosis.

Low-dose Andro strengthens Ara-C- and VCR-driven cytotoxic programs and provides a quantitative rationale for Andro-based combination strategies in plasma cell neoplasms and related hematologic malignancies.